ENDOTYPES IN CANINE ATOPIC DERMATITIS: CLINICAL PHENOTYPES AND SERUM BIOMARKER ANALYSIS

Type:
Scientific Communication
Topic:
Dermatology
Companies:
(1) Centre for Interdisciplinary Research in Animal Health (CIISA)
Authors:
Hugo Pereira (1)
Beatriz Fernandes (1)
Solange Gil (1)
Esmeralda Delgado (1)
Ana Mafalda Lourenço (1)
RESUMEN CORTO - SHORT SUMMARY:

Background: Canine atopic dermatitis (CAD) is a paradigmatic chronic inflammatory disease with wide spectrum of the clinical phenotype, disease progression and treatment responses1-4. A new approach merging both clinical phenotypes with biomarkers (endotypes) will be needed to best exploit their potential significance for CAD based and refine its management.

Objectives: To describe heterogeneity in CAD via serum biomarker profiles.

Materials and Methods: Thirty-two healthy French bulldogs and forty-four French bulldogs diagnosed with CAD were enrolled. Canine specific multiplex immune-assay was used to measure a total of 6 plasma cytokines (IFN-γ, Il-2, Il-6, Il-10, Il-18, TNF-α). Mean cytokine concentrations of healthy and CAD patients were compared. After correlation within CAD group and clinical parameters (sex, age, CADESI score, PVAS score, conjunctivitis, allergy type and allergy pattern) were performed. Statistical analysis was done using One-way ANOVA.

Results: Cytokines mean concentrations for IFN-γ, Il-2, Il-6, Il-10, Il-18, TNF-α were statistically increased in allergic pattern - low PVAS/high CADESI (LPHC). Il-10 was also increased in allergic pattern - high PVAS/low CADESI (HPLC). No difference was found between the plasma concentration of healthy and CAD dogs for these interleukins. No other clinical parameters were found significant within the CAD patients.

Conclusion: No potential biomarker was identified within these cytokines that can predict difference between a healthy dog and a canine with atopic dermatitis; or differences within atopic dermatitis parameters. Is yet to be understood if the findings in interleukins’ concentration evaluated and allergy pattern (specially in LPHC) may have a clinically interesting roll.

BIBLIOGRAFÍA:
  1. Hensel, P., Santoro, D., Favrot, C. et al. Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification. BMC Vet Res 2015; 11, 196.
  2. Wilhem S, Kovalik M, Favrot C. Breed-associated phenotypes in canine atopic dermatitis. Vet Dermatol. 2011 Apr;22(2):143-9.
  3. Favrot C, Steffan J, Seewald W, et al. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis.Vet Dermatol 2010; 21: 23–31.43.
  4. Hillier A, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XVII): intradermal testing.Vet Immunol Immunopathol 2001; 81: 289–304.
  5. Olivry T, Saridomichelakis M; International Committee on Atopic Diseases of Animals (ICADA). Evidence-based guidelines for anti-allergic drug withdrawal times before allergen-specific intra-dermal and IgE serological tests in dogs.Vet Dermatol 2013; 24:225-e49.41.
  6. Mazrier H, Vogelnest LJ, Taylor RM, et. al Altered plasma cytokines in dogs with atopic dermatitis. Vet Dermatol. 2022 Apr;33(2):131-e38.
  7. Richter KR, Nasr AN, Mexas AM. Cytokine Concentrations Measured by Multiplex Assays in Canine Peripheral Blood Samples. Vet Pathol. 2018 Jan;55(1):53-67.
  8. Wagner I, Geh KJ, Hubert M, et al. Preliminary evaluation of cytosine-phosphate-guanine oligodeoxynucleotides bound to gelatine nanoparticles as immunotherapy for canine atopic dermatitis. Vet Rec. 2017 Jul 29;181(5):118.
  9. Dias JNR, Lopes M, Peleteiro C, et al. Canine multicentric lymphoma exhibits systemic and intratumoral cytokine dysregulation. Vet Immunol Immunopathol. 2019 Dec;218:109940.
  10. Schlotter YM, Rutten VP, Riemers FM, et al. Lesional skin in atopic dogs shows a mixed Type-1 and Type-2 immune responsiveness. Vet Immunol Immunopathol. 2011 Sep 15;143(1-2):20-6.
  11. Olivry T, Dean GA, Tompkins MB, et al. Toward a canine model of atopic dermatitis: amplification of cytokine-gene transcripts in the skin of atopic dogs. Exp Dermatol. 1999 Jun;8(3):204-11.
  12. Vakirlis E, Lazaridou E, Tzellos TG, et al. Investigation of cytokine levels and their association with SCORAD index in adults with acute atopic dermatitis. J Eur Acad Dermatol Venereol. 2011 Apr;25(4):409-16.
  13. Nedoszytko   B,   Sokołowska-Wojdyło   M,   Ruckemann-Dziurdzinska K, et al. Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis. Postezpy Dermatol Alergol2014; 31: 84–91
  14. Raap U, Wichmann K, Bruder M, et al. Correlation of IL-31serum levels with severity of atopic dermatitis. J Allergy ClinImmunol2008; 122: 421–423.
  15. Frezzolini A, Paradisi M, Zaffiro A, et al. Circulating Interleukin 16(IL-16) in children with atopic/eczema dermatitis syndrome (AEDS): a novel serological marker of disease activity. Allergy 2002; 57: 815–820
  16. Kou K, Aihara M, Matsunaga T, et al. Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis. Arch Dermatol Res2012; 304:305–31.
  17. Konishi H, Tsutsui H, Murakami T, et al. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc Natl Acad Sci USA2002; 99: 11,340–11,345.35.